Claims
- 1. A method for treating hepatitis comprising administering to a patient in need thereof an effective amount of a compound that neutralizes the effect of secreted TNF alpha.
- 2. The method according to claim 1 wherein the hepatitis is selected from the group consisting of hepatitis A, hepatitis B, hepatitis C, hepatitis D, and hepatitis E.
- 3. The method according to claim 1 wherein the compound that neutralizes the effect of secreted TNF alpha is a p75:FC inhibitor.
- 4. The method according to claim 3 wherein the p75:FC inhibitor is etanercept.
- 5. The method according to claim 1 wherein the compound that neutralizes the effect of secreted TNF alpha is a humanized monoclonal antibody.
- 6. The method according to claim 5 wherein the compound is inflixamab.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims priority from provisional application Ser. No. 60/224,363, the entire contents of which are hereby incorporated.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60224363 |
Aug 2000 |
US |